Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ADVIL ALLERGY AND CONGESTION RELIEF vs TENUATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, which mediates inflammation, pain, and fever. Pseudoephedrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the nasal mucosa, causing vasoconstriction.
Tenuate (diethylpropion) is a sympathomimetic amine that acts as an appetite suppressant. It stimulates the release of norepinephrine and to a lesser extent dopamine from presynaptic nerve terminals in the hypothalamus, increasing satiety.
Temporary relief of symptoms due to hay fever or other upper respiratory allergies: nasal congestion, sinus pressure, sneezing, runny nose, itching of nose or throat, and itchy, watery eyes due to allergies.,Temporary reduction of fever.,Relief of minor aches and pains associated with the common cold, headache, toothache, muscular aches, backache, menstrual cramps, and arthritis pain.
FDA-approved: short-term (up to 12 weeks) adjunct in a regimen of weight reduction based on caloric restriction in patients with exogenous obesity.,Off-label: long-term management of obesity (not FDA-approved for extended use).
Ibuprofen 200 mg and pseudoephedrine HCl 30 mg per tablet. Usual adult dose: 1-2 tablets orally every 4-6 hours as needed, not to exceed 6 tablets in 24 hours.
25 mg orally three times daily before meals, or 75 mg extended-release orally once daily in the morning.
Ibuprofen: 2-4 hours; pseudoephedrine: 5-8 hours. Shorter half-life requires frequent dosing for sustained relief.
4-6 hours (terminal); clinical context: short half-life supports multiple daily dosing
Ibuprofen is primarily metabolized by cytochrome P450 (CYP) enzymes, mainly CYP2C9, to inactive metabolites (hydroxyibuprofen and carboxyibuprofen). Pseudoephedrine is partially metabolized in the liver by N-demethylation to an inactive metabolite.
Extensively metabolized in the liver via N-dealkylation to active metabolites (ethylaminopropiophenone and diethylaminopropiophenone). Enzymes involved include CYP3A4 and CYP2D6.
Renal excretion of unchanged drug and metabolites; approximately 1% excreted unchanged (pseudoephedrine) and 15% (ibuprofen). Biliary/fecal elimination accounts for <5%.
Renal (90% as metabolites, ~10% unchanged); minor biliary/fecal (<10%)
Ibuprofen: 99% bound to albumin; pseudoephedrine: negligible protein binding.
~92% (primarily albumin)
Ibuprofen: 0.1-0.2 L/kg; pseudoephedrine: 2.5-3 L/kg.
~4 L/kg (extensive tissue distribution, including CNS)
Oral: ibuprofen 80-100%; pseudoephedrine 100%.
Oral: ~60-70% (first-pass metabolism)
For pseudoephedrine: Cr Cl <30 m L/min, reduce dose by 50% or administer every 12 hours. For ibuprofen: avoid use if Cr Cl <30 m L/min; if Cr Cl 30-59 m L/min, use lowest effective dose and monitor renal function.
No specific guidelines; use with caution in severe renal impairment (GFR <30 m L/min) due to potential accumulation.
For ibuprofen: Child-Pugh class A and B: no adjustment necessary; Child-Pugh class C: avoid use. For pseudoephedrine: use with caution in severe hepatic impairment; no specific dose adjustment recommended, but monitor for adverse effects.
Contraindicated in Child-Pugh Class C; use with caution in Class A and B, consider dose reduction.
Not indicated for children under 12 years of age. For children 12 years and older: same as adult dose (1-2 tablets every 4-6 hours, max 6 tablets per day). Weight-based: not routinely used; safety and efficacy not established for <25 kg.
Not recommended for children under 16 years of age.
For ibuprofen: use lowest effective dose for shortest duration; monitor renal function and GI bleeding risk. For pseudoephedrine: initiate at lower doses (e.g., one tablet every 6 hours) due to increased sensitivity and risk of hypertension, urinary retention, and CNS effects.
Initial dose at 12.5 mg twice daily; titrate slowly due to increased sensitivity and risk of adverse effects.
Cardiovascular risk: NSAIDs may increase the risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. Risk increases with duration of use and in patients with cardiovascular risk factors. Contraindicated for perioperative pain in coronary artery bypass graft (CABG) surgery. Gastrointestinal risk: NSAIDs increase the risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. Elderly patients and those with prior peptic ulcer disease and/or GI bleeding are at greater risk.
There is no FDA boxed warning for Tenuate.
Cardiovascular effects: may increase risk of heart attack or stroke; use lowest effective dose for shortest duration. Gastrointestinal effects: may cause GI ulceration, bleeding, perforation. Renal effects: avoid in advanced renal disease; monitor renal function. Hepatic effects: may cause liver enzyme elevation; discontinue if liver disease develops. Anaphylactic reactions: may occur in patients with or without prior NSAID sensitivity. Asthma: may cause bronchospasm. Hypertension: may worsen hypertension. Avoid in late pregnancy due to risk of premature closure of ductus arteriosus. Pseudoephedrine: may cause nervousness, dizziness, insomnia, hypertension, arrhythmias; use with caution in patients with cardiovascular disease, diabetes, glaucoma, prostatic hypertrophy, hyperthyroidism. Avoid in severe hypertension or coronary artery disease.
Primary pulmonary hypertension: rare but serious condition associated with use.,Cardiac valvulopathy: risk increases with prolonged use or combination with other serotonergic drugs.,Tachyphylaxis: tolerance to anorectic effects may develop within a few weeks.,Psychiatric effects: may exacerbate psychiatric disorders, particularly in patients with history of substance abuse.,Seizures: risk increased in patients with epilepsy or history of seizures.
Hypersensitivity to ibuprofen, pseudoephedrine, or any component of the formulation. History of asthma, urticaria, or allergic-type reaction after taking aspirin or other NSAIDs. In the setting of coronary artery bypass graft (CABG) surgery. Severe hypertension. Coronary artery disease. Concurrent use with or within 14 days of monoamine oxidase inhibitors (MAOIs) due to risk of hypertensive crisis. Pregnancy (third trimester).
Hypersensitivity to diethylpropion or other sympathomimetic amines.,Advanced arteriosclerosis, cardiovascular disease, moderate to severe hypertension, hyperthyroidism, glaucoma.,History of drug abuse, agitated states.,Concurrent use (or within 14 days of discontinuing) MAO inhibitors (hypertensive crisis risk).
Take with food or milk to minimize GI upset. Avoid alcohol as it may increase risk of GI bleeding. No specific food-drug interactions.
Avoid caffeine and other stimulants (e.g., in coffee, tea, cola, energy drinks) as they may increase cardiovascular side effects. Avoid high-tyramine foods (e.g., aged cheeses, cured meats, fermented products) if also taking MAOIs, but this is relevant only if transitioning therapy. No specific food restrictions otherwise, but a reduced-calorie diet is essential for efficacy.
First trimester: Possible increased risk of cardiovascular malformations and gastroschisis with NSAID use. Second trimester: No specific malformation risk reported, but avoid prolonged use due to potential oligohydramnios. Third trimester: NSAIDs (including ibuprofen) are contraindicated due to risk of premature ductus arteriosus closure and oligohydramnios. Pseudoephedrine: Limited data; possible association with gastroschisis if used in first trimester; avoid due to vasoconstrictive effects.
First trimester: Limited human data, but animal studies suggest increased risk of cardiovascular and neural tube defects. Second and third trimesters: Associated with reduced fetal growth and neonatal withdrawal symptoms (tremors, hypertonia, feeding difficulties). Avoid use unless clearly needed.
Ibuprofen: Excreted in low levels (M/P ratio ~0.006); considered compatible with breastfeeding. Pseudoephedrine: Excreted in breast milk (M/P ratio ~2.5-3.5); may reduce milk production and cause irritability in infants; use with caution.
Excreted in human milk; M/P ratio not determined. Potential for adverse effects in nursing infants (e.g., irritability, poor weight gain). Use caution; decision to discontinue nursing or drug based on importance to mother.
Ibuprofen: No specific dose adjustment recommended for pregnancy; however, avoid use in third trimester. Pseudoephedrine: No dose adjustment studied; use lowest effective dose for shortest duration. Neither drug is recommended for regular use during pregnancy.
No specific pharmacokinetic data; however, pregnancy may alter metabolism. Start with lowest effective dose (25 mg BID) and monitor clinical response. Avoid sustained-release formulations due to altered GI transit.
Combination of ibuprofen (NSAID) and pseudoephedrine (decongestant). Ibuprofen may increase blood pressure, counteracting pseudoephedrine's vasoconstriction; monitor in hypertensive patients. Avoid in patients with severe CAD, uncontrolled HTN, or within 2 weeks of MAOI use.
Tenuate (diethylpropion) is a sympathomimetic amine anorectic indicated for short-term (8-12 weeks) adjunct in obesity management. Avoid in patients with history of drug abuse, cardiovascular disease, hyperthyroidism, or glaucoma. Monitor blood pressure and heart rate regularly. Tolerance may develop; discontinue if tolerance occurs. Contraindicated with MAOIs or within 14 days of their use. May impair ability to drive or operate machinery.
Do not take with other NSAIDs or cold/flu products to avoid overdose.,Pseudoephedrine may cause insomnia; take last dose at least 4-6 hours before bedtime.,Ibuprofen can cause GI bleeding; take with food or milk to reduce risk.,Stop use and consult doctor if symptoms persist >7 days or if fever lasts >3 days.,Avoid alcohol while taking this medication.
Take exactly as prescribed; do not increase dose or duration.,May cause dizziness or blurred vision; avoid driving if affected.,Inform your doctor if you have heart disease, high blood pressure, or thyroid problems.,Avoid alcohol and other CNS stimulants while taking this medication.,Report any chest pain, palpitations, or severe headache immediately.,Do not take with other appetite suppressants without consulting your doctor.,This medication is only for short-term use; combine with diet and exercise.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ADVIL ALLERGY AND CONGESTION RELIEF vs TENUATE, answered by our medical review team.
ADVIL ALLERGY AND CONGESTION RELIEF is a NSAID/Decongestant Combination that works by Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, which mediates inflammation, pain, and fever. Pseudoephedrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the nasal mucosa, causing vasoconstriction.. TENUATE is a Sympathomimetic anorectic that works by Tenuate (diethylpropion) is a sympathomimetic amine that acts as an appetite suppressant. It stimulates the release of norepinephrine and to a lesser extent dopamine from presynaptic nerve terminals in the hypothalamus, increasing satiety.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ADVIL ALLERGY AND CONGESTION RELIEF and TENUATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ADVIL ALLERGY AND CONGESTION RELIEF is: Ibuprofen 200 mg and pseudoephedrine HCl 30 mg per tablet. Usual adult dose: 1-2 tablets orally every 4-6 hours as needed, not to exceed 6 tablets in 24 hours.. The standard adult dose of TENUATE is: 25 mg orally three times daily before meals, or 75 mg extended-release orally once daily in the morning.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ADVIL ALLERGY AND CONGESTION RELIEF and TENUATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ADVIL ALLERGY AND CONGESTION RELIEF is classified as Category C. First trimester: Possible increased risk of cardiovascular malformations and gastroschisis with NSAID use. Second trimester: No specific malformation risk reported, but avoid prolo. TENUATE is classified as Category C. First trimester: Limited human data, but animal studies suggest increased risk of cardiovascular and neural tube defects. Second and third trimesters: Associated with reduced fetal. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.